Dept. of Internal Medicine (내과학교실)

Researcher List

Keyword Cloud

Journal Categories

Highly Cited Articles

Trastuzumab in combination with chemotherapy versus chemotherapy alone f...

Yung-Jue Bang ; Eric Van Cutsem ; Andrea Feyereislova ; Hyun C Chung ; Lin Sh... LANCET, Vol.376(9742) : 687-697, 2010

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

Jean-Charles Soria ; Yuichiro Ohe ; Johan Vansteenkiste ; Thanyanan Reungwetw... NEW ENGLAND JOURNAL OF MEDICINE, Vol.378(2) : 113-125, 2018

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer

S.J. Antonia ; A. Villegas ; D. Daniel ; D. Vicente ; S. Murakami ; R. Hui ; ... NEW ENGLAND JOURNAL OF MEDICINE, Vol.377(20) : 1919-1929, 2017
This table browses all dspace content
Issue DateTitleJournal Title
2025De-escalating Dual Antiplatelet Therapy to Ticagrelor Monotherapy in Acute Coronary Syndrome : A Systematic Review and Individual Patient Data Meta-analysis of Randomized Clinical TrialsANNALS OF INTERNAL MEDICINE
2025Polygenic Risk and Cardiovascular Event Risk in Patients With Atrial Fibrillation With Low to Intermediate Stroke Risk JOURNAL OF THE AMERICAN HEART ASSOCIATION
2025Circulating miR-20a-5p as a biomarker associated with cabergoline responsiveness in patients with hyperprolactinemia and pituitary adenomasEUROPEAN JOURNAL OF ENDOCRINOLOGY
2025Clinical Utility of Serum sCD200/sCD200R Ratios in Predicting Current Activity of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis JOURNAL OF CLINICAL MEDICINE
2025Association of Postprocedure Ankle-Brachial Index With Outcomes Following Drug-Coated Balloon Angioplasty in Femoropopliteal Artery DiseaseAMERICAN JOURNAL OF CARDIOLOGY
2025Factors predicting early recurrence in patients with unresectable stage III non-small cell lung cancer on durvalumab consolidation after chemoradiotherapy TRANSLATIONAL LUNG CANCER RESEARCH
2025acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter StudyCLINICAL GASTROENTEROLOGY AND HEPATOLOGY
2025Serum Biomarkers of Pulmonary Damage and Risk for Progression of Rheumatoid Arthritis-Associated Interstitial Lung DiseaseJOURNAL OF RHEUMATOLOGY
2025Targeted drug delivery using self-unrolling sheets in magnetically actuated capsulesDEVICE
2025Clinical characteristics and risk factors for escalation to anaphylaxis from non-severe drug hypersensitivity reaction CLINICAL AND TRANSLATIONAL ALLERGY
2025Ticagrelor monotherapy for acute coronary syndromes - Authors' replyLANCET
2025Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy A multicenter study for chronic hepatitis C CLINICAL AND MOLECULAR HEPATOLOGY
2025Efficacy and safety of low-dose atorvastatin plus ezetimibe for primary hypercholesterolemia: A randomized, double-blind, multicenter phase 3 trial LIPIDS
2025Treatment of IL-18-binding protein biologics suppresses fibrotic progression in metabolic dysfunction-associated steatohepatitis CELL REPORTS MEDICINE
2025HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on "Self-testing strategy to eliminate hepatitis C as per World Health Organization's goal: Analysis of disease burden and cost-effectiveness CLINICAL AND MOLECULAR HEPATOLOGY
2025Correspondence to editorial on "Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C" CLINICAL AND MOLECULAR HEPATOLOGY
2025The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver diseaseHEPATOLOGY INTERNATIONAL
2025A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
2025Risk of Variceal Bleeding in Patients Receiving Atezolizumab-Bevacizumab Treatment for Hepatocellular CarcinomaALIMENTARY PHARMACOLOGY & THERAPEUTICS
2025Clinical relevance of clinical treatment score post-5 years (CTS5) in HR-positive, HER2-positive breast cancer NPJ BREAST CANCER

Browse

Links